drugset / Trial / NCT03393481

Prevention of Thromboembolic Events in Total Knee Replacement Patients

NCT03393481

Phase 2 Withdrawn Novartis Pharmaceuticals
NaParallel-groupSingle-blindPrevention

Summary

The purpose of the study is to find out whether MAA868, is able to prevent blood clots following your medical condition (surgery for knee replacement)

Timeline

Start
2018-10-03
Primary completion
2020-01-08
Completion
2020-04-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Abelacimab Monoclonal antibody Subcutaneous
Comparator Enoxaparin sodium Other / unclassified 40 mg Subcutaneous

Indications